Clinical Characteristics and Detection of Polymerase Epsilon Mutant Endometrial Carcinoma
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Polymerase Epsilon (POLE)-mutant endometrial cancer accounts for 7%-12% of endometrial cancer molecular types, and most of these patients are early-stage endometrioid carcinoma. Although POLE-mutant endometrial cancer has some unfavorable pathological features such as being poorly differentiated, the overall prognosis is good, and postoperative adjuvant treatment may be considered for de-escalation. POLE-mutant endometrial cancer is relatively less sensitive to postoperative adjuvant chemotherapy or radiotherapy, but because of its ultra-high tumor mutation load, recurrent or advanced patients are expected to benefit from programmed cell death receptor 1 (PCDR1) blockade therapy. This review will discuss the clinical features of POLE-mutated endometrial carcinoma and the progress made in the detection of POLE gene mutations.
##plugins.themes.bootstrap3.article.details##
Endometrial Neoplasms, Molecular Classification, POLE Mutation, Prognosis, Outcomes
2. Mahdy H, Casey MJ, Crotzer D. Endometrial Cancer. [Updated 2022 Sep 26]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK525981/
3. Alexa M, Hasenburg A, Battista MJ. The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions. Cancers (Basel) 2021; 13(6):1478. DOI: https://doi.org/10.3390/cancers13061478
4. Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497(7447):67-73. DOI: https://doi.org/10.1038/nature12113. Erratum in: Nature 2013; 500(7461):242.
5. Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Chu C, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Holmes J, Howitt BE, Lea J, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Aggarwal S. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023; 21(2):181-209. DOI: https://doi.org/10.6004/jnccn.2023.0006
6. Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza MR, Ledermann JA, Colombo N; ESMO Guidelines Committee. Electronic address: [email protected]. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33(9):860-877. DOI: https://doi.org/10.1016/j.annonc.2022.05.009
7. Mur P, García-Mulero S, Del Valle J, Magraner-Pardo L, Vidal A, Pineda M, Cinnirella G, Martín-Ramos E, Pons T, López-Doriga A, Belhadj S, Feliubadaló L, Munoz-Torres PM, Navarro M, Grau E, Darder E, Llort G, Sanz J, Ramón Y Cajal T, Balmana J, Brunet J, Moreno V, Piulats JM, Matías-Guiu X, Sanz-Pamplona R, Aligué R, Capellá G, Lázaro C, Valle L. Role of POLE and POLD1 in familial cancer. Genet Med 2020; 22(12):2089-2100. DOI: https://doi.org/10.1038/s41436-020-0922-2
8. Mo S, Ma X, Li Y, Zhang L, Hou T, Han-Zhang H, Qian J, Cai S, Huang D, Peng J. Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer. J Immunother Cancer 2020; 8(2):e000881. DOI: https://doi.org/10.1136/jitc-2020-000881
9. Fu Y, Zheng Y, Wang PP, Chen YY, Ding ZY. Immunotherapy for a POLE mutation advanced non-small-cell lung cancer patient. Front Pharmacol 2022; 13:817265. DOI: https://doi.org/10.3389/fphar.2022.817265
10. Davila JI, Chanana P, Sarangi V, Fogarty ZC, Weroha SJ, Guo R, Goode EL, Huang Y, Wang C. Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing. BMC Med Genomics 2021; 14(1):165. DOI: https://doi.org/10.1186/s12920-021-01017-7
11. Erson-Omay EZ, Çağlayan AO, Schultz N, Weinhold N, Omay SB, Özduman K, Köksal Y, Li J, Serin Harmancı A, Clark V, Carrión-Grant G, Baranoski J, Çağlar C, Barak T, Coşkun S, Baran B, Köse D, Sun J, Bakırcıoğlu M, Moliterno Günel J, Pamir MN, Mishra-Gorur K, Bilguvar K, Yasuno K, Vortmeyer A, Huttner AJ, Sander C, Günel M. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro Oncol. 2015; 17(10):1356-1364. DOI: https://doi.org/10.1093/neuonc/nov027
12. Jumaah AS, Salim MM, Al-Haddad HS, McAllister KA, Yasseen AA. The frequency of POLE-mutation in endometrial carcinoma and prognostic implications: A systemic review and meta-analysis. J Pathol Transl Med 2020; 54(6):471-479. DOI: https://doi.org/10.4132/jptm.2020.07.23
13. McConechy MK, Talhouk A, Leung S, Chiu D, Yang W, Senz J, Reha-Krantz LJ, Lee CH, Huntsman DG, Gilks CB, McAlpine JN. Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Clin Cancer Res 2016; 22(12):2865-2873. DOI: https://doi.org/10.1158/1078-0432.CCR-15-2233
14. Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, D’Alessandris N, Scaglione G, Fiorentino V, Raffone A, Zannoni GF. New pathological and clinical insights in endometrial cancer in view of the updated ESGO/ESTRO/ESP Guidelines. Cancers (Basel) 2021; 13(11):2623. DOI: https://doi.org/10.3390/cancers13112623
15. Billingsley CC, Cohn DE, Mutch DG, Hade EM, Goodfellow PJ. Prognostic significance of POLE exonuclease domain mutations in high-grade endometrioid endometrial cancer on survival and recurrence: A subanalysis. Int J Gynecol Cancer 2016; 26(5):933-938. DOI: https://doi.org/10.1097/IGC.0000000000000681
16. Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, Lutgens LC, Pras E, van de Poll-Franse LV, van Putten WL; PORTEC Study Group. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011; 81(4):e631-e638. DOI: https://doi.org/10.1016/j.ijrobp.2011.04.013
17. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O’Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31(1):12-39. DOI: https://doi.org/10.1136/ijgc-2020-002230
18. Li Y, Zhu C, Xie H, Chen Y, Lv W, Xie X, Wang X. Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: A Chinese randomized phase III trial (PROBEAT). J Gynecol Oncol 2023; 34(2):e37. DOI: https://doi.org/10.3802/jgo.2023.34.e37
19. Canadian Cancer Trials Group. Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer RAINBO BLUE & TAPER. Last access: April 11, 2023. Available at: https://beta.clinicaltrials.gov/study/NCT05640999
20. Conlon N, Da Cruz Paula A, Ashley CW, Segura S, De Brot L, da Silva EM, Soslow RA, Weigelt B, DeLair DF. Endometrial carcinomas with a “serous” component in young women are enriched for DNA mismatch repair deficiency, Lynch syndrome, and POLE exonuclease domain mutations. Am J Surg Pathol 2020; 44(5):641-648. DOI: https://doi.org/10.1097/PAS.0000000000001461
21. Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, Irving JA, Malpica A, Matias-Guiu X, McCluggage WG, Mittal K, Oliva E, Parkash V, Rutgers JKL, Staats PN, Stewart CJR, Tornos C, Soslow RA. High-grade endometrial carcinomas: Morphologic and immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol 2019; 38 Suppl 1(Iss 1 Suppl 1):S40-S63. DOI: https://doi.org/10.1097/PGP.0000000000000491
22. Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecol Oncol 2017; 144(1):146-152. DOI: https://doi.org/10.1016/j.ygyno.2016.11.023
23. Van Gool IC, Rayner E, Osse EM, Nout RA, Creutzberg CL, Tomlinson IPM, Church DN, Smit VTHBM, de Wind N, Bosse T, Drost M. Adjuvant treatment for pole proofreading domain-mutant cancers: Sensitivity to radiotherapy, chemotherapy, and nucleoside analogues. Clin Cancer Res 2018; 24(13):3197-3203. DOI: https://doi.org/10.1158/1078-0432.CCR-18-0266
24. Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, Sokol ES, Frampton G, Schrock AB, Anhorn R, Reddy P. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: A review of current evidence. Oncologist 2020; 25(1):e147-e159. DOI: https://doi.org/10.1634/theoncologist.2019-0244
25. León-Castillo A, Britton H, McConechy MK, McAlpine JN, Nout R, Kommoss S, Brucker SY, Carlson JW, Epstein E, Rau TT, Bosse T, Church DN, Gilks CB. Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol 2020; 250(3):323-335. DOI: https://doi.org/10.1002/path.5372
26. Palomero J, Panisello C, Lozano-Rabella M, Tirtakasuma R, Díaz-Gómez J, Grases D, Pasamar H, Arregui L, Dorca Duch E, Guerra Fernández E, Vivancos A, de Andrea CE, Melero I, Ponce J, Vidal A, Piulats JM, Matias-Guiu X, Gros A. Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer. J Immunother Cancer 2022; 10(12):e005443. DOI: https://doi.org/10.1136/jitc-2022-005443
27. Chen Q, Wang C, Lei X, Huang T, Zhou R, Lu Y. Immune cytolytic activity for comprehensive insights of the immune landscape in endometrial carcinoma. J Oncol 2022; 2022:9060243. DOI: https://doi.org/10.1155/2022/9060243
28. Patel MV, Shen Z, Rodriguez-Garcia M, Usherwood EJ, Tafe LJ, Wira CR. Endometrial cancer suppresses CD8+ T cell-mediated cytotoxicity in postmenopausal women. Front Immunol 2021; 12:657326. DOI: https://doi.org/10.3389/fimmu.2021.657326
29. Ma X, Riaz N, Samstein RM, Lee M, Makarov V, Valero C, Chowell D, Kuo F, Hoen D, Fitzgerald CWR, Jiang H, Alektiar J, Alban TJ, Juric I, Parthasarathy PB, Zhao Y, Sabio EY, Verma R, Srivastava RM, Vuong L, Yang W, Zhang X, Wang J, Chu LK, Wang SL, Kelly DW, Pei X, Chen J, Yaeger R, Zamarin D, Zehir A, Gönen M, Morris LGT, Chan TA. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. Nat Genet 2022; 54(7):996-1012. DOI: https://doi.org/10.1038/s41588-022-01108-w
30. Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Polak M, Lee EK, Sawyer H, Bowes B, Moroney J, Cheng SC, Tayob N, Bouberhan S, Spriggs D, Penson RT, Fleming GF, Nucci MR, Matulonis UA. Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer. JAMA Oncol 2022; 8(9):1317-1322. DOI: https://doi.org/10.1001/jamaoncol.2022.2181
31. Neo-adjuvant pembrolizumab in dMMR/ POLE-EDM uterine cancer patients: A feasibility study (PAM). Last access: April 12, 2023. Available at: https://clinicaltrials.gov/ct2/show/NCT04262089
32. Cohort of tumors with POLE/D1 mutation. Last access: April 12, 2023. Available at: https://clinicaltrials.gov/ct2/show/NCT05103969
33. Carlson J, Locke AE, Flickinger M, Zawistowski M, Levy S, Myers RM, Boehnke M, Kang HM, Scott LJ, Li JZ, Zöllner S; BRIDGES Consortium. Extremely rare variants reveal patterns of germline mutation rate heterogeneity in humans. Nat Commun 2018; 9(1):3753. DOI: https://doi.org/10.1038/s41467-018-05936-5
34. Tian W, Ji Z, Wang J, Meng J, Bi R, Ren Y, Shan B, Yang G, Wang H. Characterization of hotspot exonuclease domain mutations in the DNA polymerase ϵ gene in endometrial cancer. Front Oncol 2022; 12:1018034. DOI: https://doi.org/10.3389/fonc.2022.1018034
35. Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, Grimes JM, Gorman M, Martin L, Howarth KM, Hodgson SV; NSECG Collaborators; Kaur K, Taylor J, Tomlinson IP. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum Mol Genet 2013; 22(14):2820-2828. DOI: https://doi.org/10.1093/hmg/ddt131
36. Singh RR. Target enrichment approaches for next-generation sequencing applications in oncology. Diagnostics (Basel) 2022; 12(7):1539. DOI: https://doi.org/10.3390/diagnostics12071539
37. Yao J, Gong Y, Zhao W, Han Z, Guo S, Liu H, Peng X, Xiao W, Li Y, Dang S, Liu G, Li L, Huang T, Chen S, Song L. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population. Sci Rep 2019; 9(1):15767. DOI: https://doi.org/10.1038/s41598-019-52414-z
38. León-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, Kommoss S, Brucker SY, Carlson JW, Epstein E, Rau TT, Soslow RA, Ganesan R, Matias-Guiu X, Oliva E, Harrison BT, Church DN, Gilks CB, Bosse T. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol 2020; 250(3):312-322. DOI: https://doi.org/10.1002/path.5373
39. Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilié PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers. JCO Precis Oncol 2022; 6:e2100267. DOI: https://doi.org/10.1200/PO.21.00267
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.